History of treatment and long-term outcome in children with acute lymphoblastic leukaemia in Serbia

被引：1

作者：

Micic D. ^{[1
]}

Slavkovic B. ^{[1
]}

Rasovic Gvozdenovic N. ^{[1
]}

Kuzmanovic M. ^{[1
]}

Dokmanovic L. ^{[2
]}

Krstovski N. ^{[2
]}

Skoric D. ^{[2
]}

Konstantinidis N. ^{[3
]}

Kostic G. ^{[4
]}

Predojevic J. ^{[5
]}

Janic D. ^{[2
]}

机构：

[1] Mother and Child Healthcare Institute, Belgrade

[2] Department of Hematology and Oncology, University Childrens Hospital, 11000 Belgrade

[3] Institute for Child and Youth Health Care of Vojvodina, Novi Sad

[4] Clinic for Children Internal Diseases, Nis

[5] Children Hospital, Banja Luka, Srpska

来源：

memo - Magazine of European Medical Oncology | 2011年 / 4卷 / 3期

关键词：

Acute lymphoblastic leukaemia; children; diagnostics; treatment;

D O I：

10.1007/s12254-011-0282-3

中图分类号：

学科分类号：

摘要：

Summary: We present the results of a retrospective study of ALL treatment from 1995 to 2002 according to the modified SR arm of ALL BFM 90 protocol in Serbia. Treatment was performed in five centres, two of them located in Belgrade, one in Nis, one in Novi Sad and one in neighbouring Republic of Srpska. Modification was necessary due to inadequate supply of medications and diagnostic reagents at the time and was mainly related to reduction of treatment intensity and the differences of patient stratification in comparison to the original BFM protocol. There were 462 patients, 188 of whom were girls (40.7%) and 274 boys (59.3%); median age was 5.5 years (range 1-17.9 years). In total, 98.4% patients achieved complete remission after induction treatment. Twenty patients (4.3%) died before achieving complete remission during induction treatment; additionally, there were 34 remission deaths (7.4%) and 88 relapses (19%). Median time of follow-up was 87.1 months. Ninety four patients (20.3%) were lost to follow-up (LFU). Five-year event-free survival (EFS) was 73.1% and 10-year EFS 70.5%. © 2011 Springer-Verlag.

引用

页码：174 / 177

页数：3

共 4 条

[1]

Schrappe M., Reiter A., Ludwig W.-D., Harbott J., Zimmermann M., Hiddemann W., Niemeyer C., Henze G., Feldges A., Zintl F., Kornhuber B., Ritter J., Welte K., Gadner H., Riehm H., Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: Results of trial ALL- BFM 90, Blood, 95, 11, pp. 3310-3322, (2000)

[2]

Slavkovic B., Guc-Scekic M., Djuricic S., Janic D., Gaipa G., Jankovic M., Krstic A., Tasic Z., Micic D., Bunjevacki G., Immunophenotypic and cytogenetic features of childhood acute leukemia in Serbia and Montenegro, Korean Journal of Genetics, 29, 1, pp. 99-106, (2007)

[3]

Janic D., Dokmanovic L., Jovanovic N., Et al., Results of treatment of children with acute lymphoblastic leukemia with a modified BFM protocol, Srp Arh Celok Lek, 132, SUPPL. 1, pp. 17-22, (2004)

[4]

Moricke A., Zimmermann M., Reiter A., Et al., Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000, Leukemia, 24, 2, pp. 265-284, (2010)

← 1 →